Merck Unveils HDL-Cholesterol Drug Candidates
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III trials are starting for HDL-cholesterol therapy combining extended-release niacin and anti-flushing compound and for Zocor combination.